Home > Browse Issues > Vol.42 No.8

Preclinical Research Progress of Paracrine Effect of Mesenchymal Stem Cells in Treatment of Alzheimer’s Disease

FENG Peipei^1#, CHEN Yu^1#, CHEN Yuzhan¹, HAN Shuning¹, JIANG Yue¹, FENG Jiating¹, LU Chenghao¹, HOU Ruixia¹, ZHU Yabin^1,2*

(¹Medical School of Ningbo University, Ningbo 315211, China;²Affiliated Hospital of Medical School of Ningbo University, Ningbo 315040, China)

Abstract:

AD (Alzheimer’s disease), one of common neurodegenerative diseases, severely impairs the memory and cognitive ability of patients. There are no effective drugs to cure AD, though researchers have explored for years. Paracrine growth factors, cytokines, chemokines and exosomes produced by MSCs (mesenchymal stem cells) possess the capabilities of anti-inflammatory, Aβ (β-amyloid peptide) clearance, promotion of synaptic remodeling, and antioxidant effects. They are considered to be one of the most promising clinical therapies for AD. This article firstly summarizes the pathogenesis of AD, and then reviews the preclinical studies of paracrine effect of MSC on the treatment of AD based on the characteristics and advantages of MSCs and exosomes. This review will provide valuable information for clinical treatment of AD in future.

CSTR: 32200.14.cjcb.2020.08.0016